An open-label, multicenter, randomized, phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839(sc) as monotherapy or in combination with chemotherapy plus adebelimab in patients with advanced esophageal squamous cell carcinoma (ESCC).
Capable of providing informed consent; has signed and dated the IRB/EC-approved informed consent form, and is willing and able to comply with scheduled study visits, examinations and all other protocol-specified procedures.
Aged between 18 and 75 years inclusive at the time of informed consent signature, irrespective of gender.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histopathologically confirmed locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC).
Uncontrolled or symptomatic active central nervous system (CNS) metastases without adequate prior treatment.
History of another concurrent malignant tumor diagnosed within 3 years prior to the first study drug administration.
Presence of uncontrolled tumor-related pain as assessed by the Investigator.
Severe cardiovascular or cerebrovascular diseases.